NXT007
Phase 1/2Recruiting 0 watching 0 views this week⚡ Active
41
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hemophilia A
Conditions
Hemophilia A
Trial Timeline
Sep 21, 2023 → Jun 16, 2030
NCT ID
NCT05987449About NXT007
NXT007 is a phase 1/2 stage product being developed by Roche for Hemophilia A. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05987449. Target conditions include Hemophilia A.
Hype Score Breakdown
Clinical
13
Activity
8
Company
10
Novelty
4
Community
3
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06189508 | Phase 1 | Completed |
| NCT05987449 | Phase 1/2 | Recruiting |
Competing Products
20 competing products in Hemophilia A
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Emicizumab | Chugai Pharmaceutical | Phase 3 | 77 |
| Emicizumab | Chugai Pharmaceutical | Phase 3 | 77 |
| Emicizumab + rFVIIa + aPCC | Chugai Pharmaceutical | Phase 3 | 77 |
| Human Coagulation Factor VIII | Chugai Pharmaceutical | Phase 3 | 77 |
| Emicizumab | Chugai Pharmaceutical | Phase 3 | 77 |
| Emicizumab + Factor VIII (FVIII) | Chugai Pharmaceutical | Phase 3 | 77 |
| Emicizumab | Roche | Phase 3 | 77 |
| HEMLIBRA | Johnson & Johnson | Pre-clinical | 23 |
| Emicizumab | Roche | Phase 3 | 77 |
| Emicizumab | Roche | Approved | 85 |
| Emicizumab | Roche | Phase 3 | 77 |
| SPK-8011QQ | Roche | Phase 1/2 | 41 |
| Emicizumab Injection | Roche | Phase 2 | 52 |
| Bypassing Agents + FVIII Replacement | Roche | Pre-clinical | 23 |
| PF-06741086 + PF-06741086 + PF-06741086 + PF-06741086 | Pfizer | Phase 2 | 51 |
| Nonacog Alfa (Genetical Recombination) | Pfizer | Pre-clinical | 22 |
| Refacto AF | Pfizer | Pre-clinical | 22 |
| PF-06838435/ fidanacogene elaparvovec | Pfizer | Phase 3 | 76 |
| ReFacto AF | Pfizer | Phase 3 | 76 |
| Nonacog alfa + Nonacog alfa | Pfizer | Phase 3 | 76 |